Sector News

Amneal Pharma to buy Actavis Australia’s generic pharma business

April 2, 2015
Life sciences
Amneal Pharmaceuticals Pty Ltd and Actavis Australia Pty Ltd, a subsidiary of Actavis plc, have signed a binding letter of intent which provides that Amneal intends to acquire substantially all of Actavis’ in-country generic pharmaceuticals business for an agreed price, subject to completion of confirmatory due diligence and definitive agreements.
 
Financial terms of the agreement are not available. However, both sides have agreed to work expeditiously to complete the transaction with the goal of preventing disruption of supply to existing purchasers of Actavis’ products.
 
Actavis will continue to supply the Australian market with these high quality generic medicines on the PBS and fulfill supply commitments for all hospital tenders until this transition is complete.
 
Importantly, for the non-generic business, Actavis will continue to promote and distribute branded medicines in the portfolio including but not limited to products such as Actonel and Oxytrol. A dedicated GP sales team will be maintained with the responsibility for supporting GPs and specialists who prescribe primary care products, including Actonel. Actavis will also continue to supply Botox, eye-care products and all other heritage Allergan products.
 
Amneal Pharmaceuticals LLC is a global supplier of generic pharmaceuticals, vertically-integrated across the entire supply chain from R&D to finished goods. 
 
Actavis plc, headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Actavis is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
 

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 27, 2020

AbbVie lifts insider Jeffrey Stewart to commercial chief as company veteran Carlos Alban retires

Life sciences

AbbVie will soon have a new chief commercial officer, who’ll assume the heavy responsibility of navigating the Illinois pharma’s marketing transition from megablockbuster Humira.

November 27, 2020

Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M

Life sciences

The biotech, which has a series of deals across Big Pharma, will use the voucher, which can speed up the regulatory process for a new drug, for its late-stage drug efgartigimod—but not in the indication you might think.

November 27, 2020

Galapagos sells off Fidelta as CRO activities ‘no longer fit with its strategy’

Life sciences

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita. Fidelta focuses on inflammation, fibrosis and anti-infectives, with 181 employees at the helm.

Send this to a friend